Navigation Links
Angiotech to Establish Separate Operating and Royalty Businesses

ed transaction enables Angiotech to

raise a sizable amount of gross proceeds in the form of convertible

securities that will bear non-cash interest payable in kind, and will

be convertible into shares of Angiotech's newly formed subsidiary,

API. The net proceeds that the Company elects to raise will be

utilized to reduce selected principal amounts of the two cash pay

debt securities of Angiotech currently outstanding, significantly

reducing Angiotech's cash interest expense and thereby improving

interest coverage and debt ratios.

- Retain majority API stake for Angiotech shareholders. This

transaction leaves a pro forma API initial ownership stake of between

52% and 68% for Angiotech's existing shareholders (measured

accounting for the convertible notes on an "if converted" basis at

closing). Importantly, Angiotech's existing shareholders will

continue to participate meaningfully in the success of the various

API businesses and product opportunities, including API's proprietary

Quill SRS(TM) technology and its recently approved

5-flourouracil-eluting central venous catheter.

- Mitigates risks related to Angiotech's drug-eluting stent royalty

revenue and cash flows. The debt and cash interest expense reduction

that may be achieved, combined with the significant implied equity

value of Angiotech's ownership stake in API, should improve

Angiotech's ability to continue to meet its debt obligations should

royalties received from its partner Boston Scientific Corporation

("BSC") decline from current levels as a result of additional

competitive entrants into the market for drug-eluting stents.

- Unlock and capture value embedded in Angiotech's non-TAXUS assets.

The conversion ratio of the securities issued impl

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
Post Your Comments:
(Date:8/1/2014)... The  PROPEL Center  of the  iBIO Institute , dedicated ... life sciences companies in Illinois , ... help Illinois entrepreneurs attend ... Chicago .   AdvaMed 2014 is ... , bringing more than 1,000 companies together in ...
(Date:8/1/2014)... August 1, 2014 According to ... "Biophotonics Market - Global Industry Analysis, Size, Share, Growth, ... valued at USD 25.16 billion in 2013, which is ... at a CAGR of 10.4% from 2014 to 2020. ... Increasing demand for accurate early ...
(Date:8/1/2014)... -- Research and Markets has announced the ... Genotyping and Analysis Market 2014-2018" report to their ... Single Nucleotide Polymorphism (SNP) genotyping is the screening ... genome of various species. SNPs are commonly present in ... can analyze thousands of SNPs and has the potential ...
(Date:8/1/2014)... August 01, 2014 Once a decision ... cost? This webinar will discuss how to define your ... Join speakers Bob Allen, Senior Director of Facilities Integration ... Engineering at Fluor Industrial Services, and special guest Carrier ... Planning at Amgen, as they provide an examination of ...
Breaking Biology Technology:iBIO Institute's PROPEL Center Awards Grants for AdvaMed 2014 to Early-Stage Life Sciences Companies 2iBIO Institute's PROPEL Center Awards Grants for AdvaMed 2014 to Early-Stage Life Sciences Companies 3iBIO Institute's PROPEL Center Awards Grants for AdvaMed 2014 to Early-Stage Life Sciences Companies 4Global Biophotonics Market is Expected to Reach USD 50.20 Billion in 2020: Transparency Market Research 2Global Biophotonics Market is Expected to Reach USD 50.20 Billion in 2020: Transparency Market Research 3Global Biophotonics Market is Expected to Reach USD 50.20 Billion in 2020: Transparency Market Research 4Global Single Nucleotide Polymorphism (SNP) Genotyping and Analysis Market 2014-2018 2Defining Low Cost in Your Solution for Future Facilities, New Webinar for Pharma, Biotech, Medical Device and Healthcare Companies, Hosted by Xtalks 2
... Cord Blood America, Inc . (OTC BB: CBAI, CBAID) announced ... 80 percent of its shareholders voting in a recent proxy vote, ... The one for one hundred reverse split reduces the ... A "D" will be placed on the ticker symbol ...
... BALTIMORE, May 6, 2011 Stenting is safe and ... venous stenosis in patients with deep vein thrombosis (DVT), ... Late-Breaking Clinical Trial at the Society for Cardiovascular Angiography ... EVISTA-DVT focused on patients with blocked veins ...
... Halozyme Therapeutics, Inc. (Nasdaq: HALO ), ... extracellular matrix for the diabetes, cancer, dermatology ... the first quarter 2011. (Logo: ... duration of action observed in our first ultrafast insulin ...
Cached Biology Technology:Study Shows Stents Are Superior to Balloons Alone for Patients With Deep Venous Thrombosis 2Halozyme Therapeutics Reports First Quarter 2011 Financial Results 2Halozyme Therapeutics Reports First Quarter 2011 Financial Results 3Halozyme Therapeutics Reports First Quarter 2011 Financial Results 4Halozyme Therapeutics Reports First Quarter 2011 Financial Results 5Halozyme Therapeutics Reports First Quarter 2011 Financial Results 6
(Date:8/1/2014)... cell research will provide enormous opportunities for both ... could replicate any other cells in the body, ... damaged spinal cords, treating kidney, liver and lung ... for profit is staggering. Prof. Jinhui Chen from ... of research still faces myriad biological, ethical, legal, ...
(Date:8/1/2014)... component of phloem, the conductive tissue through which plants ... Elongated cylindrical cells are capped at one end by ... tubes which in turn form a network throughout a ... special cells which play an important role in carbon ... about their differentiation," says Professor Yk Helariutta from the ...
(Date:8/1/2014)... August 1, 2014 The Journal of Nutrition Education ... Best Great Educational Material (GEM) awards, which were presented ... annual conference, "Nutrition Education Impact: Local to Global," in ... These annual awards recognize the authors of the best ... as judged by members of the JNEB Journal Committee ...
Breaking Biology News(10 mins):Developmental regulation of important plant phloem components discovered 2
... the color of ocean waters could have a drastic effect on ... such a change in one region of the North Pacific, the ... be a big drop for a region that accounts for more ... that the formation of typhoons as hurricanes are known in ...
... 13, 2010 -- Ben-Gurion University of the Negev,s (BGU) Dr. ... and Environmental Research Center (BERC) in Nablus received a significant ... the Middle East. This study brings together Israelis and Palestinians ... of Nablus over a five-year period. ...
... RICHLAND, Washington -- A little wax and soap can ... to a study in August 11 issue of ... developers to explore lower-priced alternatives to the lithium ion-metal ... a medium in which to grow good electrode materials," ...
Cached Biology News:Ocean's color affects hurricane paths 2Ocean's color affects hurricane paths 3Wax, soap clean up obstacles to better batteries 2Wax, soap clean up obstacles to better batteries 3Wax, soap clean up obstacles to better batteries 4
Request Info...
... materials necessary for the isolation and preparation of ... Kit Components: Erythrocyte ... containing 220 mL of buffered ammonium chloride. (NH ... No. 5113) One bottle containing 220 mL of ...
... with suspension (non-adherent) cells, RNA ... filtration or centrifugation to separate ... Compatible with 96-well GenePlate®. RiboCap™ ... package sizes and contain the ...
... The Zero Background/Kan Cloning Kit ... kanamycin resistance for selection in ... utilizes positive selection to eliminate ... all of the reagents you ...
Biology Products: